Early CRISPR success does not always translate into a scalable workflow. Lab managers and scientific teams must account for many factors, including reagent and enzyme quality, delivery constraints, assay throughput, data completeness and organization, and regulatory expectations. When these factors are addressed too late, or not at all, results can become difficult to reproduce, characterize, or advance toward translational and clinical milestones.
Building more reliable gene editing programs requires decisions that connect experimental design with downstream quality, analytics, and documentation needs. This eBook explores how a platform approach can help teams evaluate the components, workflows, and data infrastructure needed to move CRISPR-based programs from discovery toward clinical execution.
Download this eBook to explore:
- Reagent design and selection considerations for scalable CRISPR workflows
- Editing and delivery variables that affect accuracy, efficiency, and off-target activity
- Analytics strategies that support scalable and defensible CRISPR characterization
- Quality, documentation, and regulatory considerations for clinical execution
